Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms

被引:176
作者
Chakravarti, Arnab
Erkkinen, Michael G.
Nestler, Ulf
Stupp, Roger
Mehta, Minesh
Aldape, Ken
Gilbert, Mark R.
Black, Peter McL.
Loeffler, Jay S.
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA
[3] Univ Lausanne Hosp, Dept Multidisciplinary Oncol, Lausanne, Switzerland
[4] Univ Wisconsin, Dept Human Oncol, Madison, WI USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Neuropathol, Houston, TX 77030 USA
[6] Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
关键词
D O I
10.1158/1078-0432.CCR-06-0596
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells, Experimental Design: Using a panel of four primary human glioblastoma cell lines with heterogeneous O-6-methylguanine-DNA methyltransferase (MGMT) protein expression, normal human astrocytes, and U87 xenografts, we investigated (a) the relationship of MGMT status with efficacy of temozolomide-based chemoradiation using a panel of in vitro and in vivo assays; (b) underlying mechanisms by which temozolomide enhances radiation effect in glioblastoma cells; and (c) strategies to overcome resistance to radiation + temozolomide. Results: Temozolomide enhances radiation response most effectively in glioblastomas without detectable MGMT expression. On concurrent radiation + temozolomide administration in MGMT-negative glioblastomas, there seems to be decreased double-strand DNA (dsDNA) repair capacity and enhanced dsDNA damage compared either with radiation alone or with sequentially administered temozolomide. Our data suggest that O-6-benzylguanine can enhance the antitumor effects of concurrent radiation + temozolomide in MGMT-positive cells by enhancing apoptosis and the degree of dsDNA damage. O-6-Benzylguanine was most effective when administered concurrently with radiation + temozolomide and had less of an effect when administered with temozolomide in the absence of radiation or when administered sequentially with radiation. Our in vivo data using U87 xenografts confirmed our in vitro findings. Conclusions: The present study shows that temozolomide enhances radiation response most effectively in MGMT-negative glioblastomas by increasing the degree of radiation-induced double-strand DNA damage. In MGMT-positive glioblastomas, depletion of MGMT by the addition of O-6-benzylguanine significantly enhances the antitumor effect of concurrent radiation + temozolomide. These are among the first data showing mechanisms of synergy between radiation and temozolomide and the effect of MGMT.
引用
收藏
页码:4738 / 4746
页数:9
相关论文
共 25 条
  • [1] Tails of histones in DNA double-strand break repair
    Bilsland, E
    Downs, JA
    [J]. MUTAGENESIS, 2005, 20 (03) : 153 - 163
  • [2] Chakravarti A, 2002, CANCER RES, V62, P4307
  • [3] Chakravarti A, 2002, CANCER RES, V62, P200
  • [4] Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms
    Chakravarti, A
    Zhai, GG
    Zhang, M
    Malhotra, R
    Latham, DE
    Delaney, MA
    Robe, P
    Nestler, U
    Song, QH
    Loeffler, J
    [J]. ONCOGENE, 2004, 23 (45) : 7494 - 7506
  • [5] Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
    Chang, SM
    Lamborn, KR
    Malec, M
    Larson, D
    Wara, W
    Sneed, P
    Rabbitt, J
    Page, M
    Nicholas, MK
    Prados, MD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (02): : 353 - 357
  • [6] Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells
    Curtin, NJ
    Wang, LZ
    Yiakouvaki, A
    Kyle, S
    Arris, CA
    Canan-Koch, S
    Webber, SE
    Durkacz, BW
    Calvert, HA
    Hostomsky, Z
    Newell, DR
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (03) : 881 - 889
  • [7] Danson S J, 2001, Expert Rev Anticancer Ther, V1, P13, DOI 10.1586/14737140.1.1.13
  • [8] Friedman HS, 2000, CLIN CANCER RES, V6, P2585
  • [9] DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma
    Friedman, HS
    McLendon, RE
    Kerby, T
    Dugan, M
    Bigner, SH
    Henry, AJ
    Ashley, DM
    Krischer, J
    Lovell, S
    Rasheed, K
    Marchev, F
    Seman, AJ
    Cokgor, I
    Rich, J
    Stewart, E
    Colvin, OM
    Provenzale, JM
    Bigner, DD
    Haglund, MM
    Friedman, AH
    Modrich, PL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3851 - 3857
  • [10] HALL EJ, 2000, RADIOBIOLOGY RADIOLO, P361